SARS-CoV-2 outbreak in a nursing home after vaccination with BNT162b2: A role for the quantification of circulating antibodies

被引:3
|
作者
Camara, Jordi [1 ,2 ]
Gonzalez-Diaz, Aida [1 ,2 ]
Barrabeig, Irene [3 ,4 ]
Fernandez-Huerta, Miguel [1 ]
Calatayud, Laura [1 ,2 ]
Niubo, Jordi [1 ]
Marti, Sara [1 ,2 ]
Angeles Dominguez, Ma [1 ,5 ,6 ]
Ardanuy, Carmen [1 ,2 ,6 ]
机构
[1] Univ Barcelona, Hosp Univ Bellvitge, IDIBELL, Microbiol Dept, C Feixa Llarga S-N, Lhospitalet De Llobregat 08907, Spain
[2] ISCIII, CIBER Enfermedades Resp CIBERes, Madrid, Spain
[3] Generalitat Catalonia, Agcy Publ Hlth Catalonia, Epidemiol Surveillance & Response Publ Hlth Emerg, Barcelona, Spain
[4] ISCIII, CIBER Epidemiol & Salud Publ CIBEResp, Madrid, Spain
[5] ISCIII, CIBER Enfermedades Infecciosas CIBERinfec, Madrid, Spain
[6] Univ Barcelona, Dept Pathol & Expt Therapeut, Barcelona, Spain
关键词
SARS-CoV-2; COVID-19; Outbreak; Vaccine; B.1.351;
D O I
10.1016/j.vaccine.2022.03.026
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We describe an outbreak of SARS-CoV-2 (B.1.351) in a nursing home. At the outbreak onset 96% of residents and 76% of HCW had received two doses of BNT162b2. Twenty-eight residents (28/53) and six HCW (6/33) were infected. Infected residents had lower levels of anti-S antibodies compared to those who were not infected (157 vs 552 U/mL). Among 50 residents with available serological status, nineteen (19/25) with serum concentration < 300 U/mL and seven (7/25) with concentration > 300 U/mL acquired SARS-CoV-2 (RR 2.7 [95 %CI 1.4-5.3]). The quantification of circulating antibodies could be useful in detecting people with an impaired immune response who are at high risk of acquiring and spreading SARS-CoV-2. (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2531 / 2534
页数:4
相关论文
共 50 条
  • [31] SARS-CoV-2 infection shortly after BNT162b2 vaccination results in high anti-spike antibody levels in nursing home residents and staff
    Urlaub, Doris
    Wolfsdorff, Natalie
    Durak, Deniz
    Renken, Frank
    Watzl, Carsten
    IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1702 - 1706
  • [32] Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination
    Sanna, Giuseppina
    Marongiu, Alessandra
    Firinu, Davide
    Piras, Cristina
    Franci, Gianluigi
    Galdiero, Massimiliano
    Pala, Giuseppe
    Palmas, Vanessa
    Angius, Fabrizio
    Littera, Roberto
    Perra, Andrea
    Orru, Germano
    Campagna, Marcello
    Costanzo, Giulia
    Meloni, Federico
    Coghe, Ferdinando
    Chessa, Luchino
    Manzin, Aldo
    VACCINES, 2022, 10 (04)
  • [33] Active vitamin D analog and SARS-CoV-2 IgG after BNT162b2 vaccination in patients with hemodialysis
    Nakashima, Akio
    Yamamoto, Izumi
    Kobayashi, Arisa
    Kimura, Keita
    Yaginuma, Tatsuhiro
    Nishio, Shinichiro
    Kato, Kazuhiko
    Kawai, Rena
    Horino, Tetsuya
    Ohkido, Ichiro
    Yokoo, Takashi
    THERAPEUTIC APHERESIS AND DIALYSIS, 2024, 28 (04) : 599 - 607
  • [34] Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
    Eliakim-Raz, Noa
    Massarweh, Amir
    Stemmer, Amos
    Stemmer, Salomon M.
    JAMA ONCOLOGY, 2021, 7 (11) : 1716 - 1718
  • [35] Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women
    Goldshtein, Inbal
    Nevo, Daniel
    Steinberg, David M.
    Rotem, Ran S.
    Gorfine, Malka
    Chodick, Gabriel
    Segal, Yaakov
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (08): : 728 - 735
  • [36] High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
    Hofstee, Marloes, I
    Kaczorowska, Joanna
    Postema, Abigail
    Zomer, Erna
    van Waalwijk, Maren
    Jonathans, Gustaaf
    de Rond, Lia G. H.
    Smits, Gaby
    van den Hoogen, Lotus L.
    den Hartog, Gerco
    Buisman, Anne-Marie
    IMMUNITY & AGEING, 2025, 22 (01):
  • [37] Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection
    Perkmann, Thomas
    Perkmann-Nagele, Nicole
    Koller, Thomas
    Mucher, Patrick
    Radakovics, Astrid
    Wolzt, Michael
    Wagner, Oswald F.
    Binder, Christoph J.
    Haslacher, Helmuth
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (11)
  • [38] SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
    Falsey, Ann R.
    Frenck, Robert W., Jr.
    Walsh, Edward E.
    Kitchin, Nicholas
    Absalon, Judith
    Gurtman, Alejandra
    Lockhart, Stephen
    Bailey, Ruth
    Swanson, Kena A.
    Xu, Xia
    Koury, Kenneth
    Kalina, Warren
    Cooper, David
    Zou, Jing
    Xie, Xuping
    Xia, Hongjie
    Tuereci, Ozlem
    Lagkadinou, Eleni
    Tompkins, Kristin R.
    Shi, Pei-Yong
    Jansen, Kathrin U.
    Sahin, Ugur
    Dormitzer, Philip R.
    Gruber, William C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (17): : 1627 - 1629
  • [39] BNT162b2 Vaccine against SARS-CoV-2 effective in Children
    Meinrenken, Susanne
    PNEUMOLOGIE, 2022, 76 (03):
  • [40] Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine
    Dias, Leonor
    Soares-Dos-Reis, Ricardo
    Meira, Joao
    Ferrao, Diana
    Soares, Pedro Ribeirinho
    Pastor, Ana
    Gama, Guilherme
    Fonseca, Luisa
    Fagundes, Vitor
    Carvalho, Marta
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2021, 30 (08):